Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Research

Effects of TRAF3 on the proliferation and migration of lung adenocarcinoma depend partly on pyroptosis

Authors: Wangjia Wang, Shiqi Wang, Min Wang, Yamei Ma, Wanting Hu, Binsha Wu, Chichi Li, Dan Zhang

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Tumor necrosis factor receptor-associated factor 3 (TRAF3) has specific regulatory effects on a wide range of diseases, including tumors. However, the effect and mechanism of TRAF3 on lung adenocarcinoma (LUAD) are still unknown. The aim of the present study was to make clear the role and potential mechanism of TRAF3 in LUAD.

Methods

TIMER2.0 database and western blot were applied to detect the expression of TRAF3 in lung adenocarcinoma tissue. Kaplan-Meier Plotter database was utilized to explore the effect of TRAF3 on the clinical prognosis of lung adenocarcinoma patients. Specific siRNA was used to inhibit the expression of TRAF3 in LUAD cells (A549 and H1299). CCK-8 and EdU assays were performed for assessing LUAD cells proliferation. Wound healing assay and transwell assay were performed for determining cells migration. CCK-8 assay was used to assess the response of the LUAD cells to paclitaxel. TIMER2.0 bioinformatics and western blot were employed to detect the effects of TRAF3 on pyroptosis in LUAD.

Results

TRAF3 was highly expressed in lung adenocarcinoma tissues and cell lines. Patients with TRAF3 hyperexpression had a good prognosis compared to those with lower expression. TRAF3 inhibition notably induced proliferation and migration of LUAD cells. Inhibition of TRAF3 also weakened the sensitivity of LUAD cells to paclitaxel. Moreover, bioinformatics results showed that TRAF3 was positively correlated with the expression of pyroptosis-related genes in LUAD. Western blot assays showed that TRAF3 inhibition visibly decreased the expression of apoptosis-associated speck-like protein (ASC), cleaved caspase-1 and matured- IL-1β.

Conclusions

Inhibition of TRAF3 promotes the proliferation and migration of LUAD cells, and reduces the sensitivity of LUAD cells to paclitaxel. The effects of TRAF3 on LUAD cells were mediated in part by caspase-1-dependent pyroptosis.
Appendix
Available only for authorised users
Literature
1.
Succony L, Rassl D M, Barker A P, et al. Adenocarcinoma spectrum lesions of the lung: detection, pathology and treatment strategies [J]. Cancer Treat Rev. 2021;99:102237.CrossRefPubMed
2.
Nooreldeen R. Bach H. Current and Future Development in Lung Cancer diagnosis [J]. Int J Mol Sci, 2021, 22(16).
3.
Yang S R, Schultheis A M, Yu H, et al. Precision medicine in non-small cell lung cancer: current applications and future directions [J]. Semin Cancer Biol. 2022;84:184–98.CrossRefPubMed
4.
Herbst RS, Morgensztern D. The biology and management of non-small cell lung cancer [J]. Nature. 2018;553(7689):446–54.CrossRefPubMed
5.
Lim Z F, Ma PC. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy [J]. J Hematol Oncol. 2019;12(1):134.CrossRefPubMed
6.
7.
Kong X, Gao M, Liu Y, et al. GSDMD-miR-223-NLRP3 axis involved in B(a)P-induced inflammatory injury of alveolar epithelial cells [J]. Ecotoxicol Environ Saf. 2022;232:113286.CrossRefPubMed
8.
Zheng Z. Li G. Mechanisms and therapeutic regulation of pyroptosis in inflammatory Diseases and Cancer [J]. Int J Mol Sci, 2020, 21(4).
9.
10.
Du X, Wang S, Liu X, et al. MiR-1307-5p targeting TRAF3 upregulates the MAPK/NF-κB pathway and promotes lung adenocarcinoma proliferation [J]. Cancer Cell Int. 2020;20:502.CrossRefPubMedPubMedCentral
11.
Shi JH, Sun SC. Tumor necrosis factor Receptor-Associated factor regulation of nuclear factor κB and mitogen-activated protein kinase pathways [J]. Front Immunol. 2018;9:1849.CrossRefPubMedPubMedCentral
12.
Hacker H, Tseng P H Karinm. Expanding TRAF function: TRAF3 as a tri-faced immune regulator [J]. Nat Rev Immunol. 2011;11(7):457–68.CrossRefPubMed
13.
14.
Lalani A I, Moore C R, Luo C, et al. Myeloid cell TRAF3 regulates immune responses and inhibits inflammation and tumor development in mice [J]. J Immunol. 2015;194(1):334–48.CrossRefPubMed
15.
16.
Wang Y, Gao W, Shi X, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin [J]. Nature. 2017;547(7661):99–103.CrossRefPubMed
17.
Yu J, Li S, Qi J, et al. Cleavage of GSDME by caspase-3 determines lobaplatin-induced pyroptosis in colon cancer cells [J]. Cell Death Dis. 2019;10(3):193.CrossRefPubMedPubMedCentral
18.
19.
Wu M, Wang Y, Yang D, et al. A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma [J]. EBioMedicine. 2019;41:244–55.CrossRefPubMedPubMedCentral
20.
Whillock A L, Mambetsariev N, Lin W W, et al. TRAF3 regulates the oncogenic proteins Pim2 and c-Myc to restrain survival in normal and malignant B cells [J]. Sci Rep. 2019;9(1):12884.CrossRefPubMed
21.
Perez-Chacon G, Adrados M, Vallejo-Cremades M, T, et al. Dysregulated TRAF3 and BCL2 expression promotes multiple classes of mature non-hodgkin B cell lymphoma in mice [J]. Front Immunol. 2018;9:3114.CrossRefPubMed
22.
Zhang J, Chen T, Yang X, et al. Attenuated TRAF3 fosters activation of alternative NF-κB and reduced expression of antiviral Interferon, TP53, and RB to promote HPV-Positive Head and Neck cancers [J]. Cancer Res. 2018;78(16):4613–26.CrossRefPubMedPubMedCentral
23.
Shiode Y, Kodama T et al. Shigeno S,. TNF receptor-related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NF-κB-inducing kinase-mediated hepatocyte transdifferentiation [J]. Hepatology, 2022.
24.
Pu J, Shen J, Zhong Z, et al. KANK1 regulates paclitaxel resistance in lung adenocarcinoma A549 cells [J]. Artif Cells Nanomed Biotechnol. 2020;48(1):639–47.CrossRefPubMed
25.
Das T, Anand U, K Pandeys, et al. Therapeutic strategies to overcome taxane resistance in cancer [J]. Drug Resist Updat. 2021;55:100754.CrossRefPubMed
26.
Niu X, Wu T, Yin Q et al. Combination of Paclitaxel and PXR Antagonist SPA70 Reverses Paclitaxel-Resistant Non-Small Cell Lung Cancer [J]. Cells, 2022, 11(19).
27.
Shen Y, Liu W W, Zhang X, et al. TRAF3 promotes ROS production and pyroptosis by targeting ULK1 ubiquitination in macrophages [J]. FASEB J. 2020;34(5):7144–59.CrossRefPubMed
28.
Guan K, Wei C, Zheng Z, et al. MAVS promotes Inflammasome activation by targeting ASC for K63-Linked Ubiquitination via the E3 ligase TRAF3 [J]. J Immunol. 2015;194(10):4880–90.CrossRefPubMed
Metadata
Title
Effects of TRAF3 on the proliferation and migration of lung adenocarcinoma depend partly on pyroptosis
Authors
Wangjia Wang
Shiqi Wang
Min Wang
Yamei Ma
Wanting Hu
Binsha Wu
Chichi Li
Dan Zhang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11468-z

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

The Effect of immunonutrition in patients undergoing pancreaticoduodenectomy: a systematic review and meta-analysis

Research

An exploratory cross-sectional study of the effects of ongoing relationships with accompanying patients on cancer care experience, self-efficacy, and psychological distress

Research

Whole-exome mutational landscape and molecular marker study in mucinous and clear cell ovarian cancer cell lines 3AO and ES2

Research

Impact of CD40 gene polymorphisms on the risk of cervical squamous cell carcinoma: a case-control study

Research

Development and validation of the chemotherapy-induced peripheral neuropathy integrated assessment – oxaliplatin subscale: a prospective cohort study

Research

Plasma hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for early-stage breast cancer in a breast cancer cohort
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits